Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 85 Mendeley

Summary X Wikipedia Dimensions citations

So far, Dimensions has found 30 publications that cite this research output.

30

The most recent citing publications are shown below. View all 30 publications that cite this research output on Dimensions.

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates

Article in Medicina (March 2023)

Impact of septic episodes caused by Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa in a tertiary hospital: clinical and economic considerations in years 2018–2020

Article in Journal of Infection and Public Health (February 2023)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

Article in Frontiers in Pharmacology (October 2022)